Skip to main content
This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

Analysts Offer Insights on Technology Companies: Health In Tech, Inc. Class A (HIT) and Creative Realities (CREX)

Tipranks - Sat Apr 11, 8:42AM CDT

There’s a lot to be optimistic about in the Technology sector as 2 analysts just weighed in on Health In Tech, Inc. Class A (HIT) and Creative Realities (CREX) with bullish sentiments.

Easter Sale - 70% Off TipRanks

Health In Tech, Inc. Class A (HIT)

In a report released today, Adam Vogel from Craig-Hallum maintained a Buy rating on Health In Tech, Inc. Class A. The company’s shares closed last Thursday at $1.40, close to its 52-week low of $0.59.

According to TipRanks.com, Vogel is a 3-star analyst with an average return of 14.3% and a 81.8% success rate. Vogel covers the Healthcare sector, focusing on stocks such as LB Pharmaceuticals, Inc., Aclaris Therapeutics, and Apogee Therapeutics. ;'>

Currently, the analyst consensus on Health In Tech, Inc. Class A is a Moderate Buy with an average price target of $4.00, which is a 197.4% upside from current levels. In a report issued on March 26, TipRanks – xAI also upgraded the stock to Buy with a $2.00 price target.

See Insiders’ Hot Stocks on TipRanks >>

Creative Realities (CREX)

Craig-Hallum analyst Jason Kreyer maintained a Buy rating on Creative Realities today. The company’s shares closed last Friday at $3.50.

According to TipRanks.com, Kreyer is a 3-star analyst with an average return of 2.2% and a 36.0% success rate. Kreyer covers the Technology sector, focusing on stocks such as Gloo Holdings, Inc. Class A, Zeta Global Holdings Corp, and LiveRamp Holdings. ;'>

The the analyst consensus on Creative Realities is currently a Moderate Buy rating.

Read More on HIT:

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.